$2.4162
0.2362[10.83%]
Last update: 3:47PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$2.10
-0.3162[-13.09%]
| Open2.230 | Close- |
| Vol / Avg.110.458K / 49.319K | Mkt Cap4.655M |
| Day Range2.160 - 2.450 | 52 Wk Range1.650 - 16.000 |
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%
Agile Therapeutics Stock (NASDAQ:AGRX), Key Statistics
Agile Therapeutics Stock (NASDAQ: AGRX) analysis, key statistics.
Valuation Measures
Enterprise Value
4.1M
Trailing P/E
0.02
Forward P/E
- -
PE Ratio (TTM)
0.02
PEG Ratio (TTM)
- -
Price / Sales (ttm)
0.14
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
6326.15%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-6.29
Tangible Book value per share
-6.29
Total Liabilities (Quarterly)
24.7M
Total Assets
12.6M
Total Liabilities
24.7M
Profitability
Net income Growth
- -
Gross Margin
58.08%
Net Margin
-69.22%
EBIT Margin
-62.46%
EBITDA Margin
-60.73%
Operating Margin
-93.15%